WITH FOCUS ON X-MAS
PELOBiotech Newsletter Dec. 2018
happens if we
invest in developing
happens if we
don’t, and they
a sincere thank you for your confidence in
us and your interest in our products and services.
Wishing you, your staff and your loved ones
a reflective and restful Christmas season and
a happy and healthy New Year, bringing success
in your personal endeavors and business
Lothar, Peter and the PELOBiotech-Team
Please note due to the holiday season
our delivery times:
CW 51 (Dec 19, 2018; based upon stock)
No deliveries CW52:
Please contact us in between in urgent
matters, we are here to help.
NEW Name: Native
We have talked: New Generation of ECM Organotypic ECM
To a talk about applied 3D cell culture PELOBiotech GmbH and its US partner EastRiver BioSolutions
from New York invited to the Sky-Room at the IZB End of November 2018,. Around 30 scientists from
Munich biotech companies, the LMU, the Klinikum rechts der Isar, the Helmholtz Centre and the Hochschule
Munich discussed with
Dr. John O´Neill, CSO East River, the importance of the right physiological environment for cell growth.
Guests came from Switzerland and the University of Dublin, Ireland, Prof. Günther Eissner, too.
In his lecture on Native Organotypic ECM (Extracellular Matrix) for Coatings, Hydrogels and Scaffolds
John made it very clear how the targeted use of native coatings not only proliferates the cells but also
improves the adhesion of the cells. "You have to imagine if your cells are in a room with only brick walls.
It's not very comfortable, is it?", John O´Neill explains the functionality of his organspecific product line
compared to competitors such as Matrigel. Those offer often a cocktail disease-associated physiological
factors such as collagens. This convinced the scientists:
"The future of today's research is clearly moving in the direction of 3D," says one of the talk participants.
"The right environment for the cells is becoming increasingly important in my field," she says. Possible
applications include stem cells, tissue engineering, 3D cell culture and cancer research.
Another participant hopes to receive support for his drug screening project from the novel organoid
ECMs: "International research on pancreas organoid models is still in its infancy anyway.”
CSO John O´Neill also had a delicacy for his audience: "Very soon we will be able to offer ECMs not only
of animated but also of human origin". His colleagues Dr. Richard Nguyen, Business Development, and
EastRiver Board Member Anthony A. Curro were particularly impressed by the IZB: “The event
was a great success for us," said Anthony, who is also CEO the Biotech-company Immplacate: “It's
like old times in New York, Alexandria Biotech Center. The audience, a great campus, great people, great
atmosphere.” They will be back – soon, and then EastRiver has a new name: XYLYX Bio.
Want to know more? Browse www.pelobiotech.com or firstname.lastname@example.org
EastRiver BioSolutions is now Xylyx Bio
Our partner East River Bio has rebranded! Recognizing the importance of the native cell microenvironment,
Xylyx Bio, formerly ER Bio, is harnessing the power of tissue-specific extracellular
matrix for both drug discovery and tissue regeneration.
NativeCoat and TissueSpec® ECM substrates represent the complexity of natural extracellular
matrices and thus provide the essential cues that underlie cell function to enable cell models that
are significantly more predictive of human physiology.
Improved cell attachment
Increased cell viability and proliferation
Activation of signaling pathways
Did you know?
The new 3D
Tumour System –
WiDr offers fully validated
protocols and includes
all required components
grow tumour cells into
3D spheroids. It is ideally
suited to establish the
3D CoSeedis technology
in your lab and provides
Pic : abc biopply
3D CoSeedis: Valuable 3D Data
in Radiation Therapy Response
A recent publication in Translational Oncology (Vol. 11, No. 6, 2018;
1307 – 1322), has shown the importance of proteome studies in the investigation
of carcinoma responsiveness (pancreatic ductal adenocarcinoma,
PDAC) to chemoradiation. Important evidence was provided by
addressing the radiation resistance of A37-treated MiaPaCa-2 3D cell
aggregates in 3D CoSeedis. The publication is available under:
or contact us for further information on 3D CoSeedis and its wide range
3D aggregate formation
Maintenance of aggregates
for up to 10
Harvest of grown
The system allows to
monitor tumour growth in
real-time and to accurately
effects of treatments.
Furthermore, the system
is fully compatible with
abc biopply’s organoid
How to reach us:
If you need any further assistance or if you like what you see, tell us:
Klopferspitz 19 82152 Planegg | Germany
Tel.: +49 89 517286 59 0 | email@example.com | www.pelobiotech.com
Dr.Peter Frost HRB 197203
We like your feedback – tell us what you love, don’t like so much and what you would like to get, please.
Just reply Please update your subscription anytime, as we like to comply to the new GDPR guidelines.